October 2019 - Cancer Currents Blog
-
Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung CancerA large clinical trial showed that adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy can prolong survival in some people with previously untreated advanced small cell lung cancer.
-
PARP Inhibitors Show Promise as Initial Treatment for Ovarian CancerIn three large clinical trials of women with newly diagnosed ovarian cancer, treatment with a PARP inhibitor as first-line therapy, maintenance therapy, or both, extended the length of time before participants’ cancers came back or got worse.
-
Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple MyelomaResults from a new study suggest a potential way to improve the effectiveness of CAR T-cell therapy for multiple myeloma. The approach relies on a class of drugs called gamma-secretase inhibitors (GSIs), several of which have been studied to treat Alzheimer’s disease.
-
Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from ChemoA TAILORx analysis shows women with early-stage breast cancer and high recurrence scores on the Oncotype DX who received chemotherapy with hormone therapy had better long-term outcomes than what would be expected from hormone therapy alone.
-
Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune CellsResearchers have engineered an oncolytic virus to kill cancer cells and boost the immune response against tumors. In a new study, the virus provided T cells around tumors with a hormone they need for their own cell-killing functions.
-
HPV Vaccine May Provide Men with “Herd Immunity” against Oral HPV InfectionsOral HPV infections cause over 70% of all oropharyngeal cancers in the United States. In a new study of adults aged 18‒59, the rate of HPV vaccination rose from 0% to 6% for men, while oral HPV infections fell by 37% among unvaccinated men.
-
New on NCI's Websites for October 2019NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of October 2019.
-
After a Breast Cancer Diagnosis, Men May Be More Likely to Die than WomenMen with breast cancer may be more likely to die of the disease than women, particularly during the first 5 years after diagnosis, a new study suggests. The higher likelihood of death was linked in part to undertreatment and later diagnosis.